Hypersensitivity to the active substance or to any of the excipients listed in Description (see "Adverse Reactions").
Active pathological bleeding.
History of intracranial haemorrhage (see "Adverse Reactions").
Severe hepatic impairment (see "Dosage & Administration", "Precautions" and "Pharmacology: Pharmacokinetics under Actions").
Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir), as co-administration may lead to a substantial increase in exposure to ticagrelor (see "Interactions").